[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336239-105":59,"doc-detail-336239-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lp-184-a-novel-acylfulvene-molecule-exhibits-anticancer-activity-against-diverse-solid-tumors-with-homologous-recombination-deficiency","LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency","","Homologous recombination (HR)-related gene alterations occur in a significant subset of prostate, breast, ovarian, pancreatic, lung, and colon cancers, creating potential responsiveness to DNA-damaging agents. The acylfulvene prodrug LP-184 is metabolized to an active compound via PTGR1, often elevated in solid tumors. LP-184 increases DNA double-strand breaks in HR-deficient cells, with BRCA2 or ATM depletion yielding up to 12-fold higher sensitivity, and showing nanomolar potency across HRD models including PDX tumors. LP-184 drives complete, durable regression in multiple HRD TNBC PDXs, including PARPi-resistant cases, and synergizes with PARPi in ovarian and prostate lines. These preclinical data support clinical evaluation of LP-184 across HRD solid tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lp-184-a-novel-acylfulvene-molecule-exhibits-anticancer-activity-against-diverse-solid-tumors-with-homologous-recombination-deficiency/336239/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lp-184-a-novel-acylfulvene-molecule-exhibits-anticancer-activity-against-diverse-solid-tumors-with-homologous-recombination-deficiency/336239.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is LP-184 and how is it activated?","Question",{"text":112,"@type":113},"LP-184 is an acylfulvene prodrug that metabolizes to an active compound through PTGR1 activity, which is frequently elevated across multiple solid tumor types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does LP-184 affect HR-deficient cancer cells?",{"text":117,"@type":113},"LP-184 induces elevated DNA double-strand breaks in HR-deficient cancer cells, increasing sensitivity especially when key HR components like BRCA2 or ATM are depleted.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports LP-184 as a potential therapy across HRD tumors?",{"text":121,"@type":113},"Preclinical results show nanomolar potency across diverse HRD models, complete durable tumor regression in multiple HRD TNBC PDXs (including PARPi-resistant models), and synergy with PARP inhibitors in ovarian and prostate settings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336239,1790104368,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0554](https://doi.org/10.1158/2767-9764.CRC-23-0554)  OPEN ACCESS  \nLP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deﬁciency  \nAditya Kulkarni1 , Jianli Zhou1 , Neha Biyani1 , Umesh Kathad1 , Partha P. Banerjee2 , Shiv Srivastava2 , Zsombor Prucsi3 , Kamil Solarczyk3 , Kishor Bhatia1 ,  \nReginald B. Ewesuedo1 , and Panna Sharma1  \nCheck for updates  \nABSTRACT  \nHomologous recombination (HR)-related gene alterations are present in a significant subset of prostate, breast, ovarian, pancreatic, lung, and colon cancers rendering these tumors as potential responders to specific DNA damaging agents. A small molecule acylfulvene prodrug, LP-184, metabolizes to an active compound by the oxidoreductase activity of enzyme prostaglandin reductase 1 (PTGR1), which is frequently elevated in multiple solid tumor types. Prior work demonstrated that cancer cell lines deficient in a spectrum of DNA damage repair (DDR) pathway genes show increased susceptibility to LP-184 . Here, we investigated the potential of LP-184 in targeting multiple tumors with impaired HR function and its mechanism of action as a DNA damaging agent. LP-184 induced elevated DNA double-strand breaks in HR deficient (HRD) cancer cells. Depletion of key HR components BRCA2 or ataxia telangiectasia mutated (ATM) in cancer cells conferred up to 12-fold increased sensitivity to the LP- 184. LP-184 showed nanomolar potency in a diverse range of HRD cancer models, including prostate cancer organoids, leiomyosarcoma cell lines,  \nand patient-derived tumor graft models of lung, pancreatic, and prostate cancers. LP-184 demonstrated complete, durable tumor regression in 10 patient-derived xenograft (PDX) models of HRD triple-negative breast cancer (TNBC) including those resistant to PARP inhibitors (PARPi) . LP- 184 further displayed strong synergy with PARPi in ovarian and prostate cancer cell lines as well as in TNBC PDX models. These preclinical findings illustrate the potential of LP-184 as a pan-HRD cancer therapeutic. Taken together, our results support continued clinical evaluation of LP-184 in a large subset of HRD solid tumors.  \nSignificance: New agents with activity against DDR-deficient solid tumors refractory to standard-of-care therapies are needed. We report multiple findings supporting the potential for LP-184, a novel alkylating agent with three FDA orphan drug designations, to fill this void clinically: strong nanomolar potency; sustained, durable regression of solid tumor xenografts; synthetic lethality with HR defects. LP-184 adult phase IA trial to assess safety in advanced solid tumors is ongoing.  \nIntroduction  \nHomologous recombination (HR) is a type of DNA damage repair (DDR) pathway which plays a central role in defending and maintaining genomic stability by repairing DNA double-strand breaks (DSB; ref. 1) . Disruption in HR pathways leads to homologous recombination deficiency (HRD) associated with  \n1 Lantern Pharma Inc., Dallas, Texas. 2 Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, Washington, District of Columbia. 3 intoDNA S.A. Kraków, Poland.  \nCorresponding Author: Aditya Kulkarni, Lantern Pharma, Dallas, TX 75201 . E-mail:  \n[aditya@lanternpharma.com](aditya@lanternpharma.com)  \ndoi: 10.1158/2767-9764 .CRC-23-0554  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4 .0) license.  \n© 2024 The Authors; Published by the American Association for Cancer Research  \naccumulation of increasing levels of DNA mutations in the absence of an intact DSB repair system (2) . Advancements in genetic testing have predicted the prevalence of HRD in approximately 17.4% of tumors spanning across 21 different cancer types (3) . Prostate, breast, pancreatic, ovarian, lung cancers, and rare cancer types such as leiomyosarcomas ","cbCaimIDnHaUUk1y","https://ap.wps.com/l/cbCaimIDnHaUUk1y","pdf",12618933,12,"English","# Abstract\n## Significance\n# Introduction","[{\"question\":\"What is LP-184 and how is it activated?\",\"answer\":\"LP-184 is an acylfulvene prodrug that metabolizes to an active compound through PTGR1 activity, which is frequently elevated across multiple solid tumor types.\"},{\"question\":\"How does LP-184 affect HR-deficient cancer cells?\",\"answer\":\"LP-184 induces elevated DNA double-strand breaks in HR-deficient cancer cells, increasing sensitivity especially when key HR components like BRCA2 or ATM are depleted.\"},{\"question\":\"What evidence supports LP-184 as a potential therapy across HRD tumors?\",\"answer\":\"Preclinical results show nanomolar potency across diverse HRD models, complete durable tumor regression in multiple HRD TNBC PDXs (including PARPi-resistant models), and synergy with PARP inhibitors in ovarian and prostate settings.\"}]","LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency | PDF",1790014224,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b99a789d758c173ab5c005fc47a34aa9.webp",983,1263,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c22a942e014a6be3c42d77cfff5b06d.webp",982,1262,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e061c31898268ee4ac6d8104c77b313.webp",981,1261,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9602061ac35366ba81d7a975a3a6891c.webp",980,1259]